Significant specific markers for organ involvements
| Type of organ involvement . | Marker . | Positive . | N . | Negative . | N . | P . | Meets biomarker criteria . |
|---|---|---|---|---|---|---|---|
| Rash/lichenoid | sBAFF | 7.0 ± 5.3 | 30 | 3.5 ±3.2 | 11 | .05 | Yes |
| Scleroderma | anti-dsDNA | 5.2 ± 3.9 | 9 | 2.4 ± 2.4 | 34 | .01 | Yes |
| Joint | sBAFF | 9.9 ± 6.1 | 9 | 5.5 ± 1.0 | 32 | .02 | No |
| anti-dsDNA | 5.6 ± 4.0 | 10 | 2.2 ± 2.0 | 33 | <.001 | Yes | |
| IL-6 | 192.6 ± 270.6 | 9 | 38.8 ± 128.8 | 31 | .02 | Yes | |
| MCP-1 | 2.3 ± 3.3 | 9 | 0.98 ± 0.92 | 31 | .05 | Yes | |
| Ocular (sicca) | anti-dsDNA | 4.0 ± 3.3 | 24 | 1.7 ± 1.6 | 19 | .01 | Yes |
| anti-cardiolipin | 8.4 ± 6.2 | 24 | 4.5 ± 3.2 | 19 | .02 | No | |
| Hepatic | sBAFF | 8.6 ± 5.5 | 22 | 4.0 ± 3.8 | 19 | .004 | Yes |
| sCD13 | 0.06 ± 0.02 | 22 | 0.02 ± 0.01 | 18 | <.001 | Yes |
| Type of organ involvement . | Marker . | Positive . | N . | Negative . | N . | P . | Meets biomarker criteria . |
|---|---|---|---|---|---|---|---|
| Rash/lichenoid | sBAFF | 7.0 ± 5.3 | 30 | 3.5 ±3.2 | 11 | .05 | Yes |
| Scleroderma | anti-dsDNA | 5.2 ± 3.9 | 9 | 2.4 ± 2.4 | 34 | .01 | Yes |
| Joint | sBAFF | 9.9 ± 6.1 | 9 | 5.5 ± 1.0 | 32 | .02 | No |
| anti-dsDNA | 5.6 ± 4.0 | 10 | 2.2 ± 2.0 | 33 | <.001 | Yes | |
| IL-6 | 192.6 ± 270.6 | 9 | 38.8 ± 128.8 | 31 | .02 | Yes | |
| MCP-1 | 2.3 ± 3.3 | 9 | 0.98 ± 0.92 | 31 | .05 | Yes | |
| Ocular (sicca) | anti-dsDNA | 4.0 ± 3.3 | 24 | 1.7 ± 1.6 | 19 | .01 | Yes |
| anti-cardiolipin | 8.4 ± 6.2 | 24 | 4.5 ± 3.2 | 19 | .02 | No | |
| Hepatic | sBAFF | 8.6 ± 5.5 | 22 | 4.0 ± 3.8 | 19 | .004 | Yes |
| sCD13 | 0.06 ± 0.02 | 22 | 0.02 ± 0.01 | 18 | <.001 | Yes |
The data shows mean levels (± SD). Represents an analysis of only those patients with a particular organ involvement. Criteria for biomarkers were defined as either a 50% decrease or 100% (± 5%) increase compared to control and a P value ≤.05. Only those with a P value ≤.05 are shown in the table. There were no significant correlations of any marker with GI or lung involvement.